JAGX — Jaguar Health Share News
0.000.00%
Last trade - 00:00- $4.36m
- $14.44m
- $11.51m
Jaguar Health Inc reports results for the quarter ended December 31 - Earnings Summary
Jaguar Health Inc expected to post a loss of $18.50 a share - Earnings Preview
Jaguar Health Inc reports results for the quarter ended September 30 - Earnings Summary
Jaguar Health Inc expected to post a loss of $2.37 a share - Earnings Preview
Brief: Jaguar Health - Napo Pharmaceuticals Initiated Commercial Launch Of FDA-Approved Oral Mucositis Prescription Product Gelclair In U.S.
Jaguar Health Inc reports results for the quarter ended in June - Earnings Summary
Jaguar Health Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Jaguar Health Reports Phase 3 Ontarget Trial Results For Crofelemer
Brief: Jaguar Health Inc - Regains Compliance With Nasdaq S Bid Price Requirement
Jaguar Health Inc reports results for the quarter ended in March - Earnings Summary
Brief: Jaguar Health Files For Mixed Shelf Offering Of Up To $75 Million - SEC Filing
Brief: Iliad Research & Trading LP Reports 9.6% Passive Stake In Jaguar Health As Of Dec 29
Jaguar Health Inc reports results for the quarter ended in June - Earnings Summary
Jaguar Health Inc expected to post a loss of $1.53 a share - Earnings Preview
Brief: Jaguar Health Inc Napo Pharmaceuticals Submits Funding Application To Barda For Development Of NP-300 Drug Candidate For Cholera-Related Diarrhea
Brief: Napo Pharmaceuticals Announces Activation By FDA Of Investigational New Drug Application For Crofelemer
Brief: John Fife And Fredrick Waid Reports 9,99% Passive Stake In Jaguar Health Inc As Of May 08 - SEC Filing
Brief: Jaguar Health Inc Reports Qtrly Loss Per Share $2.39
Brief: Jaguar Health Inc - On May 10, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq